The global pharmaceutical company Novartis and its generics division Sandoz will upgrade their production network for the manufacturing of antibiotics in Europe over the next three to five years.
One of the priorities is to launch a modern process to produce oral amoxicillin, the most important form of penicillin, at its Austrian facility in Kundl, Tyrol. Accordingly, the Tyrolean site will be strengthened in its role as the interface and centre of the only consistent oral antibiotics production chain in Europe.
On balance, Novalis plans to invest more than € 150 million to sustainably safeguard the production of antibiotics in Tyrol. State-of-the-art technologies for manufacturing pharmaceutical ingredients for the leading penicillin products will be created. Conversion work will begin in the second half of 2021. The project will serve to enhance the company's long-term competitiveness and make an important contribution to the reliability of supply. Recently the expansion of the site in Kundl with the objective of transforming it into a competence centre for manufacturing nucleic acid was announced as well as the entry into the area of COVID-19 vaccine production.
Click here to view the original article.